Conjugated To Proteinaceous Toxin Or Fragment Thereof (e.g., Conjugated To Diphtheria Toxin, Pseudomonas Exotoxin, Ricin, Gelonin, Abrin, Etc.) Patents (Class 424/183.1)
-
Patent number: 8703143Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.Type: GrantFiled: August 21, 2007Date of Patent: April 22, 2014Assignee: Philogen S.p.A.Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
-
Publication number: 20140105888Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.Type: ApplicationFiled: February 17, 2012Publication date: April 17, 2014Applicant: Stem CentRx, Inc.Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
-
Patent number: 8697075Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: GrantFiled: November 16, 2011Date of Patent: April 15, 2014Assignee: Viventia Bio Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Publication number: 20140086830Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.Type: ApplicationFiled: October 23, 2013Publication date: March 27, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, Michele J. Losman, David M. Goldenberg
-
Publication number: 20140079629Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: October 29, 2013Publication date: March 20, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140072559Abstract: In an aqueous solution, a composition includes at least one protein, including at least one antibody fragment, and at least one water-soluble viscosity-reducing agent chosen from the group consisting of cytidine, 2?-deoxycytidine, uridine, 2?-deoxyuridine, thymidine and ribothymidine, alone or as a mixture. The protein includes at least one antibody fragment being at a concentration greater than or equal to 50 mg/ml.Type: ApplicationFiled: September 10, 2013Publication date: March 13, 2014Inventor: Olivier SOULA
-
Publication number: 20140065168Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: July 24, 2013Publication date: March 6, 2014Applicant: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 8663642Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.Type: GrantFiled: September 27, 2010Date of Patent: March 4, 2014Assignee: Seattle Genetics, Inc.Inventors: Che-Leung Law, Julie McEarchern, Jonathan G. Drachman
-
Publication number: 20140056905Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.Type: ApplicationFiled: January 25, 2012Publication date: February 27, 2014Applicant: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
-
Publication number: 20140044709Abstract: The present invention relates to combination therapy with paclitaxel, trastuzumab-MCC-DM1 and optionally, pertuzumab.Type: ApplicationFiled: December 7, 2011Publication date: February 13, 2014Applicant: GENENTECH, INC.Inventors: Barbara Klencke, Scott Holden, Alice Guardino, Betsy Althaus
-
Patent number: 8637027Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: November 3, 2011Date of Patent: January 28, 2014Assignee: arGEN-X B.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Patent number: 8637012Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: November 15, 2011Date of Patent: January 28, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20140017266Abstract: Recombinant scFv-immunotoxins target tumor cells expressing human podoplanin but not podoplanin-negative or normal cells. The immunotoxins can be used for treatment of malignant glioma patients or any malignant tumor expressing podoplanin. One such immunotoxin comprises a modified Pseudomonas exotoxin (PE38) attached to the scFv antibody fragment. This immunotoxin can be used as a therapeutic drug for the treatment of malignant gliomas and other cancers.Type: ApplicationFiled: December 5, 2011Publication date: January 16, 2014Applicants: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HHS, NIH, DUKE UNIVERSITYInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Vidyalakshmi Chandramohan
-
Publication number: 20140010829Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: ApplicationFiled: November 15, 2011Publication date: January 9, 2014Applicants: The Gov't of the United States, as Represented by, The Secretary of Health and Human Services, DUKE UNIVERSITYInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Publication number: 20140010756Abstract: This invention relates to a pharmaceutical composition for inhibiting the growth and/or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor ? (FR?) protein of an FR? (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FR? (+) macrophage is distributed around pancreatic cancer cells at the invasive front.Type: ApplicationFiled: March 16, 2012Publication date: January 9, 2014Inventors: Sonshin Takao, Takami Matsuyama
-
Patent number: 8617556Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.Type: GrantFiled: November 28, 2011Date of Patent: December 31, 2013Assignees: Genentech, Inc., AIMM Therapeutics B.V.Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
-
Publication number: 20130344076Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: ApplicationFiled: March 26, 2013Publication date: December 26, 2013Applicant: Viventia Bio Inc.Inventors: Francina C. CHAHAL, Jeannick CIZEAU
-
Patent number: 8613903Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.Type: GrantFiled: September 10, 2009Date of Patent: December 24, 2013Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Zhengxing Qu, Chien-Hsing Chang
-
Publication number: 20130336886Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: ApplicationFiled: May 25, 2011Publication date: December 19, 2013Applicant: UNC-CHARLOTTEInventor: Pinku Mukherjee
-
Patent number: 8609105Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.Type: GrantFiled: March 18, 2009Date of Patent: December 17, 2013Assignee: Seattle Genetics, Inc.Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
-
Patent number: 8597655Abstract: The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.Type: GrantFiled: September 22, 2011Date of Patent: December 3, 2013Assignees: Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventors: Itay Barnea, Itai Benhar, Rahamim Ben-Yosef, Akiva Vexler
-
Publication number: 20130315921Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Publication number: 20130315906Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: April 26, 2013Publication date: November 28, 2013Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Publication number: 20130315820Abstract: An antibody directed against the BDCA-2 protein for the prevention or the treatment of the pathologies involving activation of the plasmacytoid dendritic cells.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Nathalie Fournier, Christophe Romeuf
-
Patent number: 8586047Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: April 14, 2009Date of Patent: November 19, 2013Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Patent number: 8586714Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: September 1, 2010Date of Patent: November 19, 2013Assignee: ABBVIE, Inc.Inventors: Tariq Ghayur, Junjian Liu, Sharmila Manoj, Susan E. Brophy
-
Publication number: 20130287683Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: ApplicationFiled: March 15, 2013Publication date: October 31, 2013Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Patent number: 8562989Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.Type: GrantFiled: June 3, 2011Date of Patent: October 22, 2013Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid
-
Patent number: 8545850Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.Type: GrantFiled: November 5, 2010Date of Patent: October 1, 2013Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8540998Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: GrantFiled: December 24, 2008Date of Patent: September 24, 2013Assignee: Oxford Biotherapeutics Ltd.Inventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20130243774Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Edward Thein Htun van der HORST, Austin L. GURNEY, Timothy Charles HOEY, Maureen Fitch BRUHNS, Fumiko Takada AXELROD
-
Publication number: 20130236479Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.Type: ApplicationFiled: April 19, 2013Publication date: September 12, 2013Applicant: OXFORD BIOMEDICA (UK) LIMITEDInventors: Miles William Carroll, Abigail Lamikanra, Alan John Kingsman
-
Patent number: 8524241Abstract: The invention features recombinant exotoxins from Vibrio cholerae are for the therapeutic treatment of a variety of human diseases, particularly diseases characterized by an abundance or excess of undesired cells.Type: GrantFiled: July 18, 2008Date of Patent: September 3, 2013Assignee: The General Hospital CorporationInventors: Brian Seed, Jia Liu Wolfe, Chia-Lun Tsai
-
Patent number: 8524238Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: March 30, 2012Date of Patent: September 3, 2013Assignee: Celera CorporationInventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
-
Patent number: 8524240Abstract: The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).Type: GrantFiled: October 25, 2010Date of Patent: September 3, 2013Inventors: Djordje Atanackovic, Tim Luetkens
-
Publication number: 20130224111Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: ApplicationFiled: April 16, 2013Publication date: August 29, 2013Applicants: National University Corporation Yamaguchi University, National University Corporation Chiba UniversityInventors: National University Corporation Chiba University, National University Corporation Yamaguchi
-
Publication number: 20130224109Abstract: The present invention features compositions for inhibiting both the IL-6 and the IL-21 pathways and methods of making and using such compositions. Our work to date indicates the importance of the redundancy of IL-6 and IL-21 to perform certain crucial functions. The pathways can be inhibited by inhibiting the ligands (i.e., IL-6 and IL-21) and/or their respective receptors (i.e., the IL-6 receptor and IL-21 receptor). Alternatively, or in addition, upstream and downstream effectors in the IL-6 and IL-21 pathways can be blocked. The agents used can be antibody or antibody-based proteins or peptides including circulating receptors, optionally coupled to an immunoglobulin or a portion thereof (e.g., the Fc region). Also provided are methods for using the compositions, for example, in organ transplantation, tissue grafting, or autoimmune disorders.Type: ApplicationFiled: July 20, 2011Publication date: August 29, 2013Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.Inventors: Terry Strom, Maria Koulmanda
-
Patent number: 8518409Abstract: In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research.Type: GrantFiled: May 26, 2011Date of Patent: August 27, 2013Assignee: Imperium Biotechnologies, Inc.Inventor: Jacob Orme
-
Publication number: 20130216476Abstract: The use of an anti-CD71 monoclonal antibody or a fragment of an abovementioned antibody capable of binding to the CD71 antigen for the preparation of a drug intended for the prevention or treatment of myelomas.Type: ApplicationFiled: May 3, 2011Publication date: August 22, 2013Applicant: LFB BIOTECHNOLOGIESInventor: Laurence Boumsell
-
Publication number: 20130209355Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: June 8, 2011Publication date: August 15, 2013Applicant: GENMAB A/SInventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
-
Publication number: 20130202527Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: April 15, 2013Publication date: August 8, 2013Applicant: Celldex Therapeutics, Inc.Inventor: Celldex Therapeutics, Inc.
-
Publication number: 20130202626Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography.Type: ApplicationFiled: July 27, 2011Publication date: August 8, 2013Applicant: MEDIMMUNE, LLCInventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
-
Publication number: 20130202599Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: ApplicationFiled: March 18, 2013Publication date: August 8, 2013Applicant: Xencor, Inc.Inventors: Gregory Lazar, Bassil Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Publication number: 20130195872Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: NOVIMMUNE S.A.Inventor: NOVIMMUNE S.A.
-
Publication number: 20130171063Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.Type: ApplicationFiled: June 1, 2011Publication date: July 4, 2013Inventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
-
Publication number: 20130171064Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.Type: ApplicationFiled: January 16, 2013Publication date: July 4, 2013Applicant: IMMUNOMEDICS, INC.Inventor: Immunomedics, Inc.
-
Publication number: 20130164214Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.Type: ApplicationFiled: October 19, 2012Publication date: June 27, 2013Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20130164216Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: ApplicationFiled: August 12, 2011Publication date: June 27, 2013Applicant: Institute Of Biophysics, Chinese Academy Of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Patent number: 8470330Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: GrantFiled: July 28, 2010Date of Patent: June 25, 2013Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20130156784Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.Type: ApplicationFiled: July 9, 2012Publication date: June 20, 2013Inventors: Michael Jeffers, William LaRochelle